Intercept Offloads Ex-US Business To Advanz, May Be Doubling Down On NASH In US

 
• By Joseph Haas

Still working to refile its NASH fibrosis NDA 22 months after an FDA complete response letter, Intercept gets $405m up front for its ex-US business, including commercial rights to Ocaliva in PBC.

International deal
Intercept dealt ex-US rights to Ocaliva to Advanz Pharma • Source: Alamy

More from Deals

More from Business